Literature DB >> 27181198

Molecular Mechanism of HIV-1 Vpr for Binding to Importin-α.

Hideyuki Miyatake1, Akira Sanjoh2, Tomoyuki Murakami3, Hironobu Murakami3, Go Matsuda3, Kyoji Hagiwara3, Masaru Yokoyama4, Hironori Sato4, Yoichi Miyamoto5, Naoshi Dohmae6, Yoko Aida7.   

Abstract

Viral protein R (Vpr) is an accessory gene product of human immunodeficiency virus type 1 (HIV-1) that plays multiple important roles associated with viral replication. Structural studies using NMR have revealed that Vpr consists of three α-helices and contains flexible N- and C-termini. However, the molecular mechanisms associated with Vpr function have not been elucidated. To investigate Vpr multifunctionality, we performed an X-ray crystallographic study of Vpr complexes containing importin-α, a known Vpr binding partner present in host cells. Elucidation of the crystal structure revealed that the flexible C-terminus changes its conformation to a twisted β-turn via an induced-fit mechanism, enabling binding to a minor nuclear localization signal (NLS) site of importin-α. The Vpr C-terminus can also bind with major NLS sites of importin-α in an extended conformation in different ways. These results, which represent the first reported crystallographic analysis of Vpr, demonstrate the multifunctional aspects that enable Vpr interaction with a variety of cellular proteins.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  HIV-1; Vpr; accessory gene products; importin-α; induced-fit binding

Mesh:

Substances:

Year:  2016        PMID: 27181198     DOI: 10.1016/j.jmb.2016.05.003

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  8 in total

Review 1.  Retroviral vectors and transposons for stable gene therapy: advances, current challenges and perspectives.

Authors:  José Eduardo Vargas; Leonardo Chicaybam; Renato Tetelbom Stein; Amilcar Tanuri; Andrés Delgado-Cañedo; Martin H Bonamino
Journal:  J Transl Med       Date:  2016-10-12       Impact factor: 5.531

2.  HIV-1 Vpr antagonizes innate immune activation by targeting karyopherin-mediated NF-κB/IRF3 nuclear transport.

Authors:  Hataf Khan; Rebecca P Sumner; Jane Rasaiyaah; Choon Ping Tan; Maria Teresa Rodriguez-Plata; Chris Van Tulleken; Douglas Fink; Lorena Zuliani-Alvarez; Lucy Thorne; David Stirling; Richard Sb Milne; Greg J Towers
Journal:  Elife       Date:  2020-12-10       Impact factor: 8.140

3.  HIV-2/SIV Vpx antagonises NF-κB activation by targeting p65.

Authors:  Greg J Towers; Rebecca P Sumner; Douglas L Fink; James Cai; Matthew V X Whelan; Christopher Monit; Carlos Maluquer de Motes
Journal:  Retrovirology       Date:  2022-01-24       Impact factor: 4.602

4.  Huntingtin-Interacting Protein 1 Promotes Vpr-Induced G2 Arrest and HIV-1 Infection in Macrophages.

Authors:  Tomoyuki Murakami; Ryosuke Matsuura; Nopporn Chutiwitoonchai; Masami Takei; Yoko Aida
Journal:  Viruses       Date:  2021-11-19       Impact factor: 5.048

5.  HIV-1 Virus Interactions With Host Proteins: Interaction of the N-terminal Domain of the HIV-1 Capsid Protein With Human Calmodulin.

Authors:  Ywh-Min Tzou; Ronald Shin; N Rama Krishna
Journal:  Nat Prod Commun       Date:  2019-05-28       Impact factor: 0.986

6.  Protein Arginine N-methyltransferases 5 and 7 Promote HIV-1 Production.

Authors:  Hironobu Murakami; Takehiro Suzuki; Kiyoto Tsuchiya; Hiroyuki Gatanaga; Manabu Taura; Eriko Kudo; Seiji Okada; Masami Takei; Kazumichi Kuroda; Tatsuo Yamamoto; Kyoji Hagiwara; Naoshi Dohmae; Yoko Aida
Journal:  Viruses       Date:  2020-03-23       Impact factor: 5.048

7.  Distinct MCM10 Proteasomal Degradation Profiles by Primate Lentiviruses Vpr Proteins.

Authors:  Hao Chang; Lowela Siarot; Ryosuke Matsuura; Chieh-Wen Lo; Hirotaka Sato; Hiroyuki Otsuki; Yoko Aida
Journal:  Viruses       Date:  2020-01-15       Impact factor: 5.048

Review 8.  Vpr and Its Cellular Interaction Partners: R We There Yet?

Authors:  Helena Fabryova; Klaus Strebel
Journal:  Cells       Date:  2019-10-24       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.